Ultra-fractionated Radiotherapy for Rectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04677413|
Recruitment Status : Recruiting
First Posted : December 21, 2020
Last Update Posted : December 2, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Rectal Cancer||Radiation: Ultrafractionated radiotherapy for rectal cancer||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||27 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Prospective dose evaluation|
|Masking:||None (Open Label)|
|Official Title:||Phase I Trial of Ultra-fractionated Adaptive Radiotherapy, Chemotherapy and Selective Omission of Surgery for Locally Advanced Rectal Cancer|
|Actual Study Start Date :||June 3, 2021|
|Estimated Primary Completion Date :||June 2026|
|Estimated Study Completion Date :||June 2026|
Experimental: Phase I Dose Cohorts
DOSE LEVEL 1 : 30 Gy (tumor)/ 25 Gy (pelvis)
DOSE LEVEL 2 : 35 Gy (tumor)/ 25 Gy (pelvis)
DOSE LEVEL 3 : 40 Gy (tumor)/ 25 Gy (pelvis)
Radiation: Ultrafractionated radiotherapy for rectal cancer
To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
- To determine the maximal tolerated dose (MTD) of dose-escalated hypofractionated RT. [ Time Frame: 0 to 60 days post radiation therapy ]The MTD will be based upon toxicity, which will be assessed according to the NCI's CTCAE v5.0 toxicity criteria. Dose limiting toxicities will include any of the following Grade 3+ GI toxicities.
- To evaluate the rate of clinical complete and near complete response to radiation and chemotherapy. [ Time Frame: 1 year ]Clinical complete response, assessed at 4-8 weeks after completion of chemotherapy and radiation, will be defined based upon endoscopy and MRI as described in section 4.11.
- To determine the organ preservation rate at 1 year after radiotherapy and FOLFOX or CAPOX chemotherapy. [ Time Frame: 1 year ]Organ preservation rate will be defined as rate of intact rectum and no local regional failure at 1 year from completion of treatment.
- To evaluate local regional recurrence, defined as the time between date of therapy initiation and date of local progression. [ Time Frame: 1 year ]The rate of local regional recurrence will be defined as disease recurrence in the pelvis and will be recorded on a time interval since completion of treatment. This will be evaluated as a median and rate up to 1 year post treatment. The time will be backdated to when the recurrence was observed.
- To evaluate disease-free survival (DFS), defined as the time between date of therapy completion the first date of documented disease progression or death. [ Time Frame: 1 year ]The disease-free survival endpoint will be defined as the percent of patients without disease recurrence at 1-year.
- For patients undergoing surgery, to evaluate the rate of R0 resection, defined as a negative surgical margin at time of total mesorectal excision. [ Time Frame: 1 year ]R0 resection will be defined by the percent of patients with an R0 resection or negative surgical margin at the time of total mesorectal excision. Acute and late toxicities will be recorded as the rate of treatment related grade 3-5 adverse events experienced in the acute phase from initiation of therapy to 6 weeks treatment to the late phase 6 weeks to 1 year, using the NCI's CTCAE v5.0 toxicity criteria.
- To evaluate the rate of distant failure, defined as development of disease outside of the pelvis. [ Time Frame: 1 year ]The rate of distant failure will be recurrence of disease outside of the pelvis that will be collected on time interval since completion of therapy and be evaluated as a median or rate up to 1-year follow-up. Time will be backdated to when the recurrence was observed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- At least 18 years of age. Both men and women and members of all races and ethnic groups will be included.
- Willing and able to provide written informed consent
- Pathologic diagnosis of rectal adenocarcinoma
- T3-4 and/or N+ disease per AJCC 8th edition
- No prior treatment for rectal adenocarcinoma
- Eastern Cooperative Group (ECOG) performance status of 0-2.
Laboratory values supporting acceptable organ and marrow function within 30 days of eligibility confirmation. Defined as follows:
- WBC ≥ 3,000/mL;
- ANC WBC ≥ 1,000/mL;
- PLT ≥ 75,000/mL;
- T Bili ≤ 1.5 x upper limit of normal (ULN);
- AST/ALT ≤ 2.5 x ULN;
- Creatinine not above ULN, or creatinine clearance >50 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
- All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) starting with the first dose of study therapy through 90 days after the last dose of study drugs. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Distant nodal disease (retroperitoneal nodes) including inguinal nodes, or any metastatic disease by CT.
- Prior RT to the pelvis.
- Uncontrolled comorbid illness or condition including congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness that would limit compliance with the study requirements.
- Psychiatric illness/social situations that would limit consenting and compliance with study requirements.
- Participants who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04677413
|Contact: Kimberly Zepedafirstname.lastname@example.org|
|Contact: Sarah Hardeeemail@example.com|
|United States, Texas|
|UT Southwestern Medical Center||Recruiting|
|Dallas, Texas, United States, 75390-8849|
|Contact: sarah Hardee 214-645-8525 sarah.neufeld@UTSouthwestern.edu|
|Principal Investigator: Nina Sanford, M.D.|
|Principal Investigator:||Nina Sanford, MD||UT SOUTHWESTERN medical CENTRE|
|Responsible Party:||Nina Sanford, Assistant Professor, University of Texas Southwestern Medical Center|
|Other Study ID Numbers:||
|First Posted:||December 21, 2020 Key Record Dates|
|Last Update Posted:||December 2, 2022|
|Last Verified:||November 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Rectal Cancer,T3-4 or N+
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases